Liposomes as targeted drug delivery systems in the treatment of breast cancer

References

• Allen TM, Sapra P, Moase E, Moreira J, Iden D. Adventures in targeting. J Liposome Res 2002; 12: 5–12
   PubMed Web of Science ®Google Scholar
• Anabousi S, Laue M, Lehr CM, Bakowsky U, Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm 2005; 60: 295–303
   PubMed Web of Science ®Google Scholar
• Banerjee R. Liposomes: Applications in medicine. J Biomater Appl 2001; 16: 3–21
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238–252
   PubMed Web of Science ®Google Scholar
• Barth RF. A critical assessment of boron neutron capture therapy: An overview. J Neurooncol 2003; 62: 1–5
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444–1454
   PubMed Web of Science ®Google Scholar
• Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002; 324: 14–30
   PubMed Web of Science ®Google Scholar
• Bhatia A, Kumar R, Katare OP. Tamoxifen in topical liposomes: Development, characterization and in-vitro evaluation. J Pharm Pharm Sci 2004; 7: 252–259
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, Vrendenburgh J, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004; 10: 4083–4088
   PubMed Web of Science ®Google Scholar
• Budker V, Gurevich V, Hagstrom JE, Bortzov F, Wolff JA. pH-sensitive, cationic liposomes: A new synthetic virus-like vector. Nat Biotechnol 1996; 14: 760–764
   PubMed Web of Science ®Google Scholar
• Campos S. Liposomal anthracyclines: Adjuvant and neoadjuvant therapy for breast cancer. Oncologist 2003; 8: 10–16
   PubMed Web of Science ®Google Scholar
• Campbell PI. Toxicity of some charged lipids used in liposome preparation. Cytobios 1983; 37: 21–26
   PubMedGoogle Scholar
• Coombs NJ, Taylor R, Wilcken N, Boyages J. HRT and breast cancer: Impact on population risk and incidence. Eur J Cancer 2005; 41: 1775–1781
   PubMed Web of Science ®Google Scholar
• Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies. J Control Release 2003; 91: 123–133
   PubMed Web of Science ®Google Scholar
• Denny WA. The design of selectively activated prodrugs for cancer chemotherapy. Curr Pharm Des 1996; 2: 281
   Web of Science ®Google Scholar
• Derycke ASL, Witte PAM. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004; 56: 17–30
   PubMed Web of Science ®Google Scholar
• Doroshaw JH. Anthracyclines and antracenediones, in cancer chemotherapy and biotherapy: Principles and practice, BA Chabner, DL EdsLongo. Lippincott-Raven Publishers, Philadelphia 1996; 409–433
   Google Scholar
• Drummond DC, Zignani M, Leroux JC. Current status of pH sensitive liposomes in drug delivery. Prog Lipid Res 2000; 39: 409–460
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–744
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Cancer Res 1992a; 52: 891–896
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992b; 15: 891–896
   Google Scholar
• Gabizon AA, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004; 56: 1177–1192
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81: 1484–1488
   PubMed Web of Science ®Google Scholar
• Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 2002; 8: 3611–3621
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309–318
   PubMed Web of Science ®Google Scholar
• Goyal P, Goyal K, Kumar SGV, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems:Clinical applications. Acta Pharm 2005; 55: 1–25
   PubMedGoogle Scholar
• Gregoriadis G. Overview of liposomes. J Antimicrob Chemother 1991; 28: 39–48
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes as immunoadjuvants and vaccine carriers: Antigen entrapment. J Immunol Methods 1994; 4: 210–216
   Google Scholar
• Gregoriadis G, Florence AT. Liposomes and cancer therapy. Cancer Cells 1991; 4: 144–146
   Google Scholar
• Harris J, Lippman M, Morrow M, Osborne C. Diseases of the breast. Lippincott Williams & Wilkins, Philadelphia, PA 2000
   Google Scholar
• Harris L, Winer E, Batist G, Rovira D, Navaria R, Lee L. Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC). Proc Am Soc Clin Oncol 1998; 17: 124
   Google Scholar
• Hauck ML, Dewhirst MW, Bigner DD, Zalutsky ML. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res 1997; 3: 63–70
   PubMed Web of Science ®Google Scholar
• Hewitt M, Breen N, Devesa S. Cancer prevalence and survivorship issues: Analysis of the 1992 national health interview survey. J Natl Cancer Inst 1999; 91: 1480–1486
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci 1998; 95: 4607–4612
   PubMed Web of Science ®Google Scholar
• Hortobaygi GN. Drug thearpy. N Engl J Med 1998; 339: 974–984
   PubMed Web of Science ®Google Scholar
• Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res 1993; 134: 143–150
   PubMed Web of Science ®Google Scholar
• Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Huang L, Dihua Y. HER-2/neu-targeting gene therapy-a review. Gene 1995; 159: 65–71
   PubMed Web of Science ®Google Scholar
• Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 2003; 91: 417–429
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241–263
   PubMed Web of Science ®Google Scholar
• Jardines L, Callans LS, Torosian MH. Recurrent breast cancer: Presentation, diagnosis, and treatment. Semin Oncol 1993; 20: 538–547
   PubMed Web of Science ®Google Scholar
• Jones M. Carbohydrate mediated liposomal targeting and drug delivery. Adv Drug Deliv Rev 1994; 13: 215–250
   Web of Science ®Google Scholar
• Jurcic JG, Larson SM, Sgouros G. Targeted alpha-particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233–1239
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Koukouraki S, Giatromanolaki A. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas. Acta Oncol 2000; 39: 207–211
   PubMed Web of Science ®Google Scholar
• Kozubek A, Gubernator J, Przeworska E, Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 2000; 47: 639–649
   PubMed Web of Science ®Google Scholar
• Lag R, Kosary CKL, Hankey BF. 1999. SEER Cancer Statistics Review 1973-1996, National Cancer Institute, Bethesda, MD USA, http://seer.cancer.gov/csr/1973_1996/
   Google Scholar
• Langner M, Kral TE. Liposome-based drug delivery systems. Pol J Pharmacol 1999; 51: 211–222
   PubMedGoogle Scholar
• Legendre JY, Szoka FC. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes. Pharm Res 1992; 9: 1235–1242
   PubMed Web of Science ®Google Scholar
• Leopold KA, Dewhirst MW, Samulski TV, Harrelson J, Tucker JA, George SL, Dodge RK, Grant W, Clegg S, Prosnitz LR, et al. Relationship among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1992; 22: 989–998
   PubMed Web of Science ®Google Scholar
• Menezes DEL, Hudon N, Cintosh NM, Mayer N. Pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal Doxorubicin. Clin Cancer Res 2000; 6: 2891–2902
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229
   PubMed Web of Science ®Google Scholar
• Muggia FM. Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced premeability and retention. Clin Cancer Res 1999; 5: 7–8
   PubMed Web of Science ®Google Scholar
• Mymryk JS. Tumor suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 1996; 13: 1581–1589
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1197–1201
   PubMed Web of Science ®Google Scholar
• Needham D, Dewhirst MW. The development and testing of a new temperature sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53: 285–305
   PubMed Web of Science ®Google Scholar
• Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C, Seliger B. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies?. Cancer Res 1998; 58: 4090–4095
   PubMed Web of Science ®Google Scholar
• Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid U, Ahmad I. Systemic delivery of Raf-si RNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005; 26: 1087–1091
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Gabizon AA. Targeting of liposomes to tumor cells in vivo. Ann NY Acad Sci 1987; 507: 64–74
   PubMed Web of Science ®Google Scholar
• Parbhoo S. Breast cancer overview. Cancerkin, Royal Free Hospital, London 2005; 1–8
   Google Scholar
• Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002a; 4: 95–99
   PubMed Web of Science ®Google Scholar
• Park JW. The potential of drug-carrying immunoliposomes as anticancer agents. Clin Cancer Res 2002b; 8: 955–956
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci 1995; 92: 1327–1331
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Shalaby R, Colbern G, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, et al. Anti-HER2 immunoliposomes: Enhanced anticancer efficacy due to targeted delivery. Clin Cancer Res 2002; 8: 1172–1181
   PubMed Web of Science ®Google Scholar
• Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001; 74: 95–113
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2002; 55: 74–108
   Web of Science ®Google Scholar
• Parr MJ, Masin D, Cullis P, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinomas: The lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 1997; 280: 1319–1327
   PubMed Web of Science ®Google Scholar
• Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection. AAPS J 2004; 6: 1–10
   PubMed Web of Science ®Google Scholar
• Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPS J 2005; 7: 61–77
   PubMed Web of Science ®Google Scholar
• Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int J Rad Appl Instrum B 1992; 19: 539–547
   PubMedGoogle Scholar
• Ranson MR, Carmichael J, Byrne KO, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185–3191
   PubMed Web of Science ®Google Scholar
• Reinhold HS, Endrich B. Tumor microcirculation as a target for hyperthermia. Int J Hyperthermia 1986; 2: 111–137
   PubMedGoogle Scholar
• Reubi JC. In vitro identification of VIP receptors in human tumors: potential clinical implications. Ann NY Acad Sci 1996; 805: 753–759
   PubMed Web of Science ®Google Scholar
• Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FL, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, et al. Phase 1 study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 2001; 19: 1716–1722
   PubMed Web of Science ®Google Scholar
• Rooijen van N, Nieuwmegen van R. Liposomes in immunology: Multilamellar phosphatidylcholine liposome as a simple biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol Commun 1980; 9: 243–256
   PubMedGoogle Scholar
• Sharma A, Straubinger RM, Ojima I, Bernacki RJ. Antitumor efficacy of taxane liposomes on a human ovarian tumour xenograft in nude athymic mice. J Pharm Sci 1995; 84: 1400–1404
   PubMed Web of Science ®Google Scholar
• Shaughnessy JO. Liposomal anthracyclines for breast cancer: Overview. Oncologist 2003; 8: 1–2
   Web of Science ®Google Scholar
• Sihorkar V, Vyas SP. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J Pharm Pharm Sci 2001; 4: 138–158
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S. Usr of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar
• Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential alpha particle therapy of metastatic cancer. J Nucl Med 2004; 45: 253–260
   PubMed Web of Science ®Google Scholar
• Soler RP, Francis K, Baker S, Ilkiewicz FP, Khokhar AR. Preparation and characterization of liposomes containing a lipophillic cisplatin derivative for clinical use. J Microencapsul 1994; 11: 41–54
   PubMed Web of Science ®Google Scholar
• Springer CJ, Niculescu-Duvaz I. Antibody-directed enzyme prodrug therapy (ADEPT): A review. Adv Drug Deliv Rev 1997; 26: 151–172
   PubMed Web of Science ®Google Scholar
• Strobel ES, Fritschka E. Hereditary premenopausal breast cancer. J Cancer Res Treat 2002; 25: 24–2747
   Google Scholar
• Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: A clinical perspective. Crit Rev Oncol Hematol 1992; 12: 231–242
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Zhou F, Huang L. pH-Sensitive liposomes. J Liposome Res 1993; 3: 201–205
   Google Scholar
• Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell penetrating peptides penetratin and tat: A kinetic and efficacy study. Mol Pharmacol 2002; 62: 864–872
   PubMed Web of Science ®Google Scholar
• Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene1. Cancer Res 2002; 62: 6712–6716
   PubMed Web of Science ®Google Scholar
• Vives E, Brodin P, Lebleu B. A truncated HIV-1 tat protein basic domain rapidly translocates through plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010–16017
   PubMed Web of Science ®Google Scholar
• Wolff AC. Liposomal anthracyclines and new treatment approaches for breast cancer. Oncologist 2003; 8: 25–30
   PubMed Web of Science ®Google Scholar
• Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in longcirculating pegylated liposomes. J Pharmacol Exp Ther 1999; 289: 1128–1133
   PubMed Web of Science ®Google Scholar
• Yanagie H, Kobayashi H, Takeda Y, Yoshizaki I, Nonaka Y, Naka S, Nojiri A, Shinnkawa H, Furuya Y, Niwa H. Inhibition of growth of human breast cancer cells in culture by neutron capture using liposomes containing 10B. Biomed Pharmacother 2002; 56: 93–99
   PubMed Web of Science ®Google Scholar
• Yuan F, Lwunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352–3356
   PubMed Web of Science ®Google Scholar
• Zalipsky S, Hansen CB, Menezes DEL, Allen TM. Long-circulating, polyethylene glycol-grafted immunoliposomes. J Control Release 1996; 39: 153–161
   Web of Science ®Google Scholar
• http://www.rxlogix.com/delivery_sample02.html. Assessed on 30th Jan 06.
   Google Scholar
• http://www.cancer.org/downloads/STT/CAFF2003BrFPWSecured.pdf. Assessed on 30th Jan 06.
   Google Scholar
• http://www.wsws.org/articles/2003/apr2003/canc-a26.shtml. Assessed on 30th Jan 06.
   Google Scholar